-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Viking Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2017 to Q1 2025.
- Viking Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $349K, a 99.9% decline year-over-year.
- Viking Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $612M, a 126% increase from 2023.
- Viking Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $271M, a 6419% increase from 2022.
- Viking Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $4.16M, a 39.5% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)